Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Jazz Pharmaceuticals PLC JAZZ
News
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting
Jazz Pharmaceuticals Celebrates Pride Month With Discussion, Education and Allyship
Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
Jazz Pharmaceuticals Honors the Invaluable Contributions of the AAPI Community Within Healthcare and Beyond
Jazz Pharmaceuticals Hosts Discussion of Healthcare Inequities in the U.S. To Honor Juneteenth
Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
Jazz Pharmaceuticals Publishes 2023 Corporate Sustainability and Social Impact Report: Progress, Responsibility and Innovation
Solar stocks plunge after SolarEdge warning, as Urgent.ly and Knight-Swift stocks soar and more companies on the move
Jazz Pharmaceuticals Gets European Commission OK for Enrylaze
United States